Said Beydoun, MD
Clinical Neurophysiology · Los Angeles, CANPI 1700827482
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $692,628 of the $985,489 with a category attached, or 70.3%. It is spread thinly across 24 manufacturers, the largest accounting for just 21.2%. Among clinical neurophysiology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 890 payments — averaging $1107.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$209K
- CSL Behring$126K
- UCB, Inc.$115K
- Takeda Pharmaceuticals U.S.A., Inc.$108K
- Alnylam Pharmaceuticals Inc.$98K
- Argenx US, Inc.$83K
- plus $246K from 18 others
Across 271 payments — averaging $5453.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$370K
- Novartis$172K
- Sanofi$143K
- AstraZeneca$115K
- Janssen Research & Development, LLC$108K
- Sanofi US Services Inc.$98K
- plus $472K from 11 others
What the payments were for
- Consulting fees$204,69621%
- Speaking & faculty fees$692,62870%
- Travel & lodging$65,3957%
- Food & beverage$22,4422%
- Education$3290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 173 | $208,816 |
| CSL Behring | 95 | $125,747 |
| UCB, Inc. | 101 | $115,332 |
| Takeda Pharmaceuticals U.S.A., Inc. | 99 | $107,955 |
| Alnylam Pharmaceuticals Inc. | 78 | $98,148 |
| Argenx US, Inc. | 81 | $83,149 |
| Akcea Therapeutics, Inc. | 75 | $79,539 |
| Tanabe Pharma America, Inc. | 43 | $41,080 |
| Grifols USA, LLC | 24 | $22,535 |
| Johnson & Johnson | 23 | $18,046 |
| Shire North American Group Inc | 17 | $17,979 |
| Amylyx Pharmaceuticals, Inc. | 20 | $16,445 |
| Amgen | 12 | $13,150 |
| Biogen | 9 | $8,154 |
| Janssen Global Services, LLC | 7 | $8,044 |
| Pfizer | 3 | $7,100 |
| Octapharma USA, Inc. | 6 | $4,842 |
| Catalyst Pharmaceuticals, Inc. | 4 | $3,870 |
| Genentech, Inc. | 4 | $3,856 |
| Janssen Scientific Affairs, LLC | 2 | $1,116 |
| Grifols Shared Services North America, Inc. | 6 | $394 |
| Sanofi | 2 | $129 |
| Sanofi-aventis U.S. LLC | 1 | $59 |
| Travere Therapeutics, Inc. | 5 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hizentra$121,802
- ULTOMIRIS$119,049
- TEGSEDI$78,241
- VYVGART$76,851
- ONPATTRO$59,433
- HYQVIA$53,726
- Rystiggo$53,222
- GAMMAGARD LIQUID$43,439
- Radicava$39,958
- WAINUA$39,498
- AMVUTTRA$32,707
- SOLIRIS$26,897
- Zilbrysq$22,426
- Gamunex-C$21,694
- Privigen$16,909
- RELYVRIO$16,248
- UPLIZNA$7,844
- PANZYGA$6,221
- OCTAGAM IMMUNE GLOBULIN (HUMAN)$5,721
- SPINRAZA$4,792
How this compares
$985,489 in reported general payments places this provider in the 95th percentile of 49 clinical neurophysiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 87 | $1,228,966 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 123 | $1,108,713 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 20 | $420,051 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 37 | $401,155 |
| HyqviaIgg/Hyaluronidase,recombinant | 20 | $279,026 |
| RelyvrioSod Phenylbutyrat/Taurursodiol | 15 | $217,996 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 36 | $146,425 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 12 | $115,948 |
| Riluzole | 13 | $19,358 |
| Prednisone | 21 | $274 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $22,535 | $1,108,713123 claims |
| CSL BehringPrivigen, Hizentra | $125,747 | $547,58073 claims |
| PfizerPanzyga | $7,100 | $420,05120 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Hyqvia | $107,955 | $279,02620 claims |
| Amylyx Pharmaceuticals, Inc.Relyvrio | $16,445 | $217,99615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 49 clinical neurophysiology providers in California.
Other clinical neurophysiology in Los Angeles
- Christopher LockStanford$159K
- Srikanth MuppidiStanford$150K
- Mitchell MiglisStanford$51K
- Michael AminoffSan Francisco$41K
- Safwan JaradehStanford$34K
- Sadiq AltamimiPomona$30K
- Margaret FerrisStanford$18K
- Kathleen PostonStanford$18K
- Alexander GevorgyanGlendale$14K
- Loveneet SinghFresno$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.